Path ID: DB05541_MESH_D004828_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:C482793 | Brivaracetam | Drug |
| UniProt:Q7L0J3 | Synaptic vesicle glycoprotein 2A | Protein |
| GO:0005248 | Voltage-gated sodium channel activity | MolecularActivity |
| GO:0007269 | Neurotransmitter secretion | BiologicalProcess |
| HP:0001250 | Seizure | PhenotypicFeature |
| MESH:D004828 | Partial seizure | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Brivaracetam | NEGATIVELY REGULATES | Synaptic Vesicle Glycoprotein 2A |
| Brivaracetam | NEGATIVELY REGULATES | Voltage-Gated Sodium Channel Activity |
| Synaptic Vesicle Glycoprotein 2A | PARTICIPATES IN | Neurotransmitter Secretion |
| Voltage-Gated Sodium Channel Activity | POSITIVELY CORRELATED WITH | Seizure |
| Neurotransmitter Secretion | CORRELATED WITH | Partial Seizure |
| Seizure | MANIFESTATION OF | Partial Seizure |
Comment: The precise mechanism of brivaracetam’s anti-epileptogenic activity is unknown. It is thought that brivaracetam binds to SV2A and causes the reduction in the rate of vesicle release including release of excitatory neurotransmitters.
Reference: